Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[EGFR/HER1: a target life].

Bulletin du cancer - 1 Feb 2012

Viel Erika, Curtit Elsa, Mansi Laura, Vignot Stéphane

Abstract excerpt

EGFR may be considered as an old target, which can be inhibited both by monoclonal antibodies and tyrosine kinase inhibitors. Those molecular targeted strategies are now approved in a wild range of tumors: colorectal cancer, lung cancer, pancreatic cancer and head and neck cancer. This paper proposes to describe the development of anti-EGFR drugs, highlighting several strategies points. Predicting biomarkers have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Erlotinib Hydrochloride
Share to Panitumumab
Share to Pyrazines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Angiogenesis Inhibitors

Share to Bevacizumab

Share to Boronic Acids

Share to Bortezomib

Share to Cetuximab

Source

Identifiers

PMID: 21684835
DOI: 10.1684/bdc.2011.1385

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[EGFR/HER1: a target life].PMID 21684835Read ↗

Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023?Semantic proximity Read ↗

INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in breast Cancer: Therapeutic challenges and way forward.Semantic proximity Read ↗

Advances in EGFR/HER2-directed clinical research on breast cancer.Semantic proximity Read ↗

The epidermal growth factor receptor pathway: a model for targeted therapy.Semantic proximity Read ↗

EGFR signaling pathway as therapeutic target in human cancers.Semantic proximity Read ↗

[Targeted therapies and non-small cell carcinomas : novelties].Semantic proximity Read ↗

Rational bases for the development of EGFR inhibitors for cancer treatment.Semantic proximity Read ↗

Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.Semantic proximity Read ↗

Cancer molecular markers: A guide to cancer detection and management.Semantic proximity Read ↗

Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.Semantic proximity Read ↗

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.